A Systematic Approach To Promoting Home Hemodialysis during End Stage Kidney Disease.

Home dialysis has garnered much attention since the advent of the Advancing American Kidney Health initiative. For many patients and nephrologists, home dialysis and peritoneal dialysis are synonymous. However, home hemodialysis (HHD) should not be forgotten. Since 2004, HHD has grown more rapidly than other dialytic modalities. The cardinal feature of HHD is customizability of treatment intensity, which can be titrated to address the vexing problems of volume and pressure loading during interdialytic gaps and ultrafiltration intensity during each hemodialysis session. Growing HHD utilization requires commitment to introducing patients to the modality throughout the course of ESKD. In this article, we describe a set of strategies for introducing HHD concepts and equipment. First, patients initiating dialysis may attend a transitional care unit, which offers an educational program about all dialytic modalities during 3-5 weeks of in-facility hemodialysis, possibly using HHD equipment. Second, prevalent patients on hemodialysis may participate in "trial-run" programs, which allow patients to experience increased treatment frequency and HHD equipment for several weeks, but without the overt commitment of initiating HHD training. In both models, perceived barriers to HHD-including fear of equipment, anxiety about self-cannulation, catheter dependence, and the absence of a care partner-can be addressed in a supportive setting. Third, patients on peritoneal dialysis who are nearing a transition to hemodialysis may be encouraged to consider a home-to-home transition (

Informations de copyright

Copyright © 2020 by the American Society of Nephrology.

Déclaration de conflit d'intérêts

M. Carver reports employment at Fresenius Medical Care North America. J. Glickman reports being on the medical advisory board of Cricket Health, speaker honorarium from Home Dialysis University, and authorship of UpToDate content. M. Kraus reports employment at Fresenius Medical Care North America. R. Lockridge reports speaker honoraria from DaVita Kidney Care, Fresenius Medical Care North America, and NxStage Medical. B. Miller reports speaker honoraria from DaVita Kidney Care, Fresenius Medical Care Renal Therapies Group, and Home Dialysis University; and authorship of UpToDate content. M. Schreiber reports employment at DaVita Kidney Care. L. Spry reports stock in a for-profit joint venture, Lincoln Nephrology Investments, regarding a facility offering only home dialysis. P. Tailor reports scientific advisory board of NxStage Medical. E. Weinhandl reports epidemiologic research consultancy to Fresenius Medical Care North America.